Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Raised by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 37.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 114,222 shares of the company's stock after acquiring an additional 31,183 shares during the period. TimesSquare Capital Management LLC owned 0.40% of Krystal Biotech worth $20,792,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Swiss National Bank lifted its position in Krystal Biotech by 0.8% during the 1st quarter. Swiss National Bank now owns 36,200 shares of the company's stock valued at $6,441,000 after acquiring an additional 300 shares during the period. Sei Investments Co. grew its holdings in Krystal Biotech by 128.3% during the first quarter. Sei Investments Co. now owns 33,752 shares of the company's stock valued at $6,005,000 after purchasing an additional 18,968 shares during the period. Headlands Technologies LLC bought a new stake in Krystal Biotech during the first quarter valued at about $291,000. ProShare Advisors LLC boosted its stake in shares of Krystal Biotech by 9.0% in the first quarter. ProShare Advisors LLC now owns 5,865 shares of the company's stock worth $1,044,000 after acquiring an additional 486 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its stake in shares of Krystal Biotech by 18.5% in the first quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company's stock worth $1,300,000 after acquiring an additional 1,140 shares during the period. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded down $3.74 during mid-day trading on Monday, reaching $195.87. The stock had a trading volume of 295,122 shares, compared to its average volume of 330,190. The firm has a market capitalization of $5.63 billion, a price-to-earnings ratio of 112.35 and a beta of 0.82. Krystal Biotech, Inc. has a twelve month low of $95.02 and a twelve month high of $219.34. The business has a 50 day simple moving average of $181.29 and a 200 day simple moving average of $180.86.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the firm posted ($0.67) EPS. The company's quarterly revenue was up 879.9% compared to the same quarter last year. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 14.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KRYS. Evercore ISI boosted their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Chardan Capital raised their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a research report on Monday, August 5th. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Finally, Stifel Nicolaus lifted their price objective on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $197.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).